How has Composting Grown and What is its Future?

 


The word “sustainability,” is on the tip of everyone’s tongues lately. Commerce and business worldwide are looking for better and cheaper ways to keep business viable into the future. Industries like agriculture, architecture, civic design, and others are starting to catch on to the cost-effective and high-performing product that is compost.

Today’s guests are Ryan Cerrato, VP of Product Marketing for Denali Water Solutions, and Rod Tyler, President & Owner of Green Horizons Environmental. They talk about how the compost industry has evolved, where it is innovating, and the surprising use-cases that make compost a super substance.

Composting, in short, is “nature’s oldest form of recycling,” said Tyler. When organic compounds decompose, the resulting product is a nutrient-rich fertilizer. The value of compost has increased tremendously over the past 30 years. Demand is up, agree Cerrato and Tyler. The practice of composting takes much-needed pressure off landfills. It also helps grow vegetation and kills bacteria, ending the transfer to future generations. The goal of compost is to stay as local to the composting facilities as possible, making the industry’s carbon footprint remarkably small. The sustainable mission of the compost industry is attracting bright young minds eager to start a career that is in harmony with Earth’s natural sciences.

What’s more, composting is expanding into new high-value markets. Engineers and architects are seeing the benefit of incorporating it into their designs, and are returning to the reliable product time and time again. From urban farming to erosion control, compost has many use-cases. Young minds and innovators are continuing to find new markets and products that benefit from the sustainable commodity.

In today’s economy where many industries are currently in question, composting remains one of Earth’s oldest and most reliable practices, producing healthy, natural vegetation in a holistic life cycle.

For the latest news, videos, and podcasts in the Sciences Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More